KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $36.5 million.

  • Recursion Pharmaceuticals' Depreciation & Amortization (CF) rose 192.35% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.2 million, marking a year-over-year increase of 148.18%. This contributed to the annual value of $36.5 million for FY2024, which is 49.55% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Depreciation & Amortization (CF) of $36.5 million as of FY2024, which was up 49.55% from $24.4 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $36.5 million during FY2024, and its lowest value of $3.9 million during FY2020.
  • Over the past 3 years, Recursion Pharmaceuticals' median Depreciation & Amortization (CF) value was $24.4 million (recorded in 2023), while the average stood at $24.2 million.
  • Data for Recursion Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY soared of 113.16% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Depreciation & Amortization (CF) stood at $3.9 million in 2020, then spiked by 113.16% to $8.4 million in 2021, then surged by 39.87% to $11.8 million in 2022, then spiked by 107.57% to $24.4 million in 2023, then skyrocketed by 49.55% to $36.5 million in 2024.